HBIO (Harvard Bioscience) שולי הרווח הגולמי

Harvard Bioscience generates revenue by supplying monitoring systems and cell research equipment to universities and pharmaceutical laboratories. Quarterly gross margins demonstrate capital management efficiency, while 54.20 reflects the current value of this metric. The business faces trade barriers between the US and China, as well as risks associated with Asian optics supplies. Simultaneously, Harvard Bioscience is implementing high-margin solutions for precision dosing and biomedical analysis.
פילוחי מדדים פיננסיים ומדדי שוק עבור Harvard Bioscience, Inc. (HBIO)

Gross margin measures production efficiency by determining the portion of revenue remaining after direct costs, allowing investors to assess the business's fundamental ability to generate profit. An analysis of the gross margin ratio confirms the pricing power of Harvard Bioscience (HBIO), driven by its gold-standard status and the supply of indispensable equipment to the world's leading pharmaceutical laboratories.